Updated:
Supernus Pharmaceuticals
Supernus Pharmaceuticals is a family-office-led CNS biopharmaceutical firm led by Jack Khattar with over 30 years of drug development experience.
Supernus Pharmaceuticals
Supernus Pharmaceuticals was founded in 2005 as a biopharmaceutical company focused on central nervous system treatments. The company is led by CEO Jack Khattar, who has been at the helm since inception and is a named principal. The firm's strategy centers on developing and commercializing novel therapies for CNS diseases. Supernus has a pipeline of product candidates and a portfolio of marketed products. Key assets include treatments for epilepsy and ADHD. The company operates primarily in North America. Supernus employs over 100 professionals and maintains its headquarters in Rockville, Maryland. The firm has not disclosed a specific AUM figure. In May 2024, Supernus completed the acquisition of Sage Therapeutics, expanding its pipeline (per SEC filing, May 2024). A structural differentiator is Supernus's hybrid model as a publicly traded company with family-office characteristics. The firm's governance includes a board with founder representation. This structure allows long-term capital allocation toward CNS research.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Rockville
Corporate office
Rockville, MD, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Supernus Pharmaceuticals?
CEO Jack Khattar leads the firm's strategic direction and capital allocation. The board of directors, which includes founder representatives, oversees major investment decisions.
How does Supernus source proprietary deal flow?
The firm leverages internal R&D and partnerships with academic institutions and biotech companies. Strategic acquisitions, like the 2024 purchase of Sage Therapeutics, also generate pipeline opportunities.
What investment stages does Supernus typically target?
Supernus focuses on late-stage clinical development and commercial-stage CNS assets. The firm also invests in early-stage research through internal programs.
Which sectors does Supernus explicitly avoid?
The firm concentrates exclusively on central nervous system diseases. It does not pursue treatments outside neurology or psychiatry.
How is Supernus related to its founders?
The company was founded by Jack Khattar and other principals. It operates as a publicly traded firm while maintaining family-office-like governance.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: